This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Close

AboutAboutAbout APEXXNARMechanism of actionClinical programmeClinical programmeAPEXXNAR clinical study overviewAPEXXNAR adverse drug reactionsAdministration
Pneumococcal conjugate vaccines like APEXXNAR® are designed to deliver  long-lasting immunity1,2APEXXNAR first

Vaccinating with a pneumococcal conjugate vaccine first has been shown to enhance the immune response of a subsequent pneumococcal polysaccharide vaccine administered 1 year later. 

PPSV23 first

Conversely, vaccinating with a pneumococcal polysaccharide vaccine first followed by a conjugate 1 year later can diminish the immune response compared to the conjugate vaccine alone.

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Refer to section 4.8 for how to report adverse reactions.References:APEXXNAR® Summary of Product Characteristics. Froes F, Roche N, Blasi F. Pneumococcal vaccination and chronic respiratory diseases. Int J Chron Obstruct Pulmon Dis. 2017;12:3457-3468.ClinicalTrials.gov. Trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults. Available at https://clinicaltrials.gov/ct2/show/NCT03760146. Last Accessed: August 2022ClinicalTrials.gov. Trial to evaluate the safety and immunogenicity of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults. Available at https://clinicaltrials.gov/ct2/show/NCT03828617. Last Accessed: August 2022ClinicalTrials.gov. Trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal vaccine in adults 65 years of age or older with prior pneumococcal vaccination. Available at https://clinicaltrials.gov/ct2/show/NCT03835975. Last Accessed: August 2022About Study overview

APEXXNAR was evaluated for safety and immunogenicity across a diverse patient population.1,3-5

 Review the data Loading View Summary of Product Characteristics  Apexxnar® Loading Prevenar 13® Loading Patient profiles

See why certain patients may be at greater risk for pneumococcal disease.7

 Meet the patients Loading

Legal Category: S1A
Further information is available upon request

PP-PNR-IRL-0015 Date of Preparation: August 2022

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0733. March 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare profressional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0733 . March 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0733. March 2024